网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
曲妥珠单抗联合FOLFOX方案治疗HER-2阳性晚期胃癌的疗效及安全性研究
作者:王燕艳1  郭联斌2  谭世余2 
单位:1. 安康职业技术学院, 陕西 安康 725000;
2. 安康市中心医院 消化内科, 陕西 安康 725000
关键词:晚期胃癌 曲妥珠单抗 FOLFOX方案 HER-2阳性 安全性 
分类号:R735.2
出版年·卷·期(页码):2019·47·第二期(170-174)
摘要:

目的:探讨曲妥珠单抗联合FOLFOX方案治疗人表皮生长因子受体-2(HER-2)阳性晚期胃癌的疗效及安全性。方法:将70例HER-2阳性晚期胃癌患者随机分为两组,对照组35例行FOLFOX方案化疗,即奥沙利铂+亚叶酸钙+5-氟尿嘧啶治疗,观察组35例在对照组基础上加以曲妥珠单抗治疗,对比两组治疗效果,治疗前后KPS评分、肿瘤标志物水平和毒副反应发生情况。结果:观察组与对照组的近期客观总有效率(57.14% vs 40.00%)和疾病控制率(80.00% vs 68.57%)比较有统计学意义(P<0.05);观察组治疗后的KPS评分较对照组显著提高(P<0.05);治疗后观察组的肿瘤标志物(CA724、CA199、CEA)水平显著低于对照组(P<0.05);两组胃肠道反应、骨髓抑制及感觉神经毒性发生率相当(P<0.05),观察组心脏毒性、发热或寒战、皮疹毒性反应发生率分别为14.29%、22.86%和25.71%,显著高于对照组的2.86%、5.71%和2.86%。结论:曲妥珠单抗联合FOLFOX方案治疗HER-2阳性晚期胃癌效果显著,可显著提高近期疗效和KPS评分,但会增加心脏毒性、寒战等药物毒性反应发生率。

Objective:To evaluate the efficacy and safety of trastuzumab combined with FOLFOX regimen in the treatment of human epidermal growth factor receptor-2(HER-2) positive advanced gastric cancer.Methods:70 patients with HER-2 positive advanced gastric cancer were randomly divided into two groups. In the control group, 35 patients underwent FOLFOX chemotherapy. Namely oxaliplatin+leucovorin+5-fluorouracil treatment, on top of which 35 patients in the observation group were treated with trastuzumab. The therapeutic effect, the KPS score, the tumor marker level and the toxic and side effects were compared between the two groups.Results:The objective total effective rate(57.14% vs 40.00%) and the disease controlling rate(80.00% vs 68.57%) in the two groups were statistically significant(P<0.05). After treatment, the KPS score of the observation group was significantly higher than that of the control group(P<0.05);after treatment, the levels of tumor markers(CA724, CA199, CEA) in the observation group were significantly lower than those in the control group(P<0.05);there was no significant difference in the incidence of gastrointestinal reactions, myelosuppression and sensory nerve toxicity between the two groups(P<0.05),the incidence of cardiac toxicity, fever or chills and rash toxicity in the observation group were 14.29%, 22.86% and 25.71%, respectively, which was significantly higher than 2.86%, 5.71% and 2.86% in the control group. Conclusion:Trastuzumab combined with FOLFOX regimen is effective in the treatment of HER-2 positive advanced gastric cancer, which can significantly improve the short-term efficacy and KPS score, but increase the incidence of toxic reactions such as heart toxicity, chills and so on.

参考文献:

[1] 孙杰,潘赛英,陈倩琪,等.曲妥珠单抗联合FOLFIRI治疗HER2阳性晚期胃癌的疗效观察[J].南方医科大学学报,2011,31(8):1458-1460.
[2] 刘泽锋,徐越超,芦晋,等.曲妥珠单抗治疗人表皮生长因子受体-2高表达胃癌的研究进展[J].中国老年学杂志,2013,33(3):723-725.
[3] 左强,罗宇玲,谢剑明,等.Her-2阳性胃癌细胞株对曲妥珠单抗药物敏感性的实验研究[J].热带医学杂志,2013,13(8):936-938.
[4] 陆向东,赵韬,张瑶,等.曲妥珠单抗联合化疗治疗人表皮生长因子受体2阳性的晚期胃或胃食管结合部腺癌的临床观察[J].江苏医药,2017,43(6):444-445.
[5] 冯睿,张小田,杨升,等.胃癌靶向治疗的研究现状与进展[J].中华胃肠外科杂志,2016,19(10):1191-1196.
[6] 李森,李治国,成龙,等.Her-2阳性胃癌靶向治疗的研究进展[J].实用肿瘤学杂志,2015,29(2):188-192.
[7] 邱佳宁,韩涛,刘璐,等.曲妥珠单抗联合多西他赛加顺铂治疗HER-2阳性晚期胃癌相关射血分数降低与疗效关系[J].临床军医杂志,2017,45(1):34-37.
[8] 张琦,徐智,陈锦飞,等.胃癌药物治疗进展[J].癌症进展,2014,10(1):22-28.
[9] 韩真真,袁胜利,丁明翠,等.曲妥珠单抗对HER-2高表达胃癌细胞珠抑制作用观察[J].中华肿瘤防治杂志,2013,20(8):593-595.
[10] 魏微,闫泽强.曲妥珠单抗联合IP化疗方案治疗HER-2阳性晚期胃癌的疗效观察[J].现代药物与临床,2017,32(3):505-508.
[11] 马磊,马雯,陈文晟,等.曲妥珠单抗联合多西他赛/S-1二线治疗进展期胃癌的初步研究[J].海南医学,2015,23(15):2209-2211.
[12] 朱丽波,马锐,李琳琳,等.曲妥珠单抗联合奥沙利铂、5-氟尿嘧啶治疗HER-2/neu高表达晚期胃癌的临床疗效观察[J].疑难病杂志,2013,12(12):930-932.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 265965 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541